company profile · company profile 1. about the company karian pharmaceuticals is a fast growing...

COMPANY PROFILECOMPANY PROFILE

1

ABOUT THE COMPANY ABOUT THE COMPANY

KARIAN PHARMACEUTICALS is a fast growing pharmaceutical company in Greece.company in Greece.

Our vision is to work under a modern and dynamic business model, and create one of the most efficient pharmaceutical model, and create one of the most efficient pharmaceutical companies in Greece & the South Eastern Europe Region.

Paradeisou 3, Agia ParaskeviAthens, Greece 2

HISTORYHISTORY

KARIAN PHARMACEUTICALS founded by people with a new understanding and thinking about a pharmaceutical company. understanding and thinking about a pharmaceutical company. With long experience in the pharmaceutical market, these executives envisioned a company with a high sense of responsibility to promote public health and to benefit the social responsibility to promote public health and to benefit the social community.

Five years later, KARIAN is one of the most rapid pharmaceutical Five years later, KARIAN is one of the most rapid pharmaceutical companies in Greece, with a growth of more than 25% per year.


OUR BUSINESS ACTIVITIES (1) OUR BUSINESS ACTIVITIES (1)

KARIAN business is closely aligned with market needs. The activities are focused in areas such as: needs. The activities are focused in areas such as:

Marketing and distribution of pharmaceutical products Pharmaceuticals substances Pharmaceuticals substances Healthcare and laboratory supplies Diagnostics and Medical devices OTC products OTC productsMarketing and distribution of veterinary products.


OUR BUSINESS ACTIVITIES (2)OUR BUSINESS ACTIVITIES (2)

And also focused in areas such as:

Consultancy business services Scientific and technical services supportMarket Analysis Market Analysis Development of technical chemical studies.


OUR BUSINESS MODEL OUR BUSINESS MODEL

KARIAN PHARMACEUTICALS is active in promoting and distributing innovative high standard pharmaceutical products, distributing innovative high standard pharmaceutical products, which introduces in the Greek market, representing the largest pharmaceutical companies.

In parallel, we build partnerships with multinational companies, and also with worldwide recognized producers for the promotion and distribution of generic medicines, and innovative promotion and distribution of generic medicines, and innovative products.


OUR STRATEGYOUR STRATEGY

KARIAN strategy is focused on transactions that add targeted value to KARIAN pipeline and capabilities. These transactions value to KARIAN pipeline and capabilities. These transactions reflects strategic areas of research and business development.

The continuously expanding range of innovative products in combination with the already existing strong partnerships and combination with the already existing strong partnerships and accountability of the executives is the key of the company for a sustainable and successful development.sustainable and successful development.


OUR CORE BUSINESSOUR CORE BUSINESS

KARIAN PHARMACEUTICALS is one of the main vendors of the National Organization of Medicines (EOF) the National Organization of Medicines (EOF)

Our effort is to fulfill doctors and patients needs and to facilitate and cover the demands of Greek Authorities, with high facilitate and cover the demands of Greek Authorities, with high quality drugs, produced by manufacturers, with respect to Good Manufacturing Procedures, delivering the quantities needed just in time and in low pricing, for the goods of people’s health just in time and in low pricing, for the goods of people’s health and of the society as a whole.


DISTRIBUTION PRODUCTS IN GREECE DISTRIBUTION PRODUCTS IN GREECE

KARIAN PHARMACEUTICALS product portfolio includes original & generic medicines in 6 therapeutics includes original & generic medicines in 6 therapeutics areas: Central Nervous System, Cardiology, Cardiology, Orthopedics- Rheumatology, Surgical Analgesia- Anesthesia Internal Medicine.Internal Medicine.Antiparasitic drugs



CENTRAL NERVOUS SYSTEM

Akineton, (Biperidene), tab, 2mg BT X50Akineton, (Biperidene), tab, 2mg BT X50Akineton, ( Biperidene), tab, 4mg BT X 50Akineton, (Biperidene), inj sol, 5mg/1ml AMP, in Parkinson Disease & Extrapyramidal Symptoms from Pharmacological CausePharmacological Cause



CENTRAL NERVOUS SYSTEM

Prazine, (Promazine), tab, 25 mg, BT X 50, Antipsychotic Prazine, (Promazine), tab, 25 mg, BT X 50, Antipsychotic Prazine, (Promazine), tab, 50 mg, BT X 50, Antipsychotic



CARDIOLOGY Colchicina Acarpia, (Colchicine), tab, 1 mg, BT X 30, Gout ArhritisColchicina Lirca, ( Colchicine), tab, 1 mg BT X 30,/ BT X 60 Gout Arthritis Colchicina Acarpia is the same product with Colchicina LircaColchicina Acarpia is the same product with Colchicina LircaExtended clinical evidence support it’s use in pericarditis, Mediterranean Fever and BehcetDisease Leading Research Groups in Greece and Abroad using colchicines in protocols in patients with COVID-19. COVID-19.



CARDIOLOGY

Trinitrina, (Nitroglycerine), inj sol inf 50mg/50ml X 5 vials x 50ml, Vasodilator of Coronary Arteries 50ml, Vasodilator of Coronary Arteries Urokinase, (Urokinase), 25.000 U.I./2ml pwd for inj, Thrombolytic Urokinase, (Urokinase), 100.000 U.I./2ml pwd for inj, Urokinase, (Urokinase), 100.000 U.I./2ml pwd for inj, Thrombolytic Urokinase, (Urokinase), 1.000.000 U.I./2ml pwd for inj, Thrombolytic Thrombolytic Heparin Sodium, (Heparin Sodium), Vials, 2.500.00 iu/5 mlNot registered & circulated in Greek Market



ORTHOPEDICS & RHEUMATOLOGY Dargol, (Alendronic Acid), tab, 70 mg, BT X 4, Biphosphate, Anti- osteoporotic Anti- osteoporotic

Pancuronium, (Pancuronium Bromide), Sol, iv inj, 4mg/ 2ml, Muscle RelaxantMuscle RelaxantNot registered & circulated in Greek Market



INTERNAL MEDICINE Phenergan, (Promethazine), syr, 0, 1% syrop, Anti- histamine Phenergan inj, (Promethazine), 2, 5% injectable box of 5 Phenergan inj, (Promethazine), 2, 5% injectable box of 5 Amps / 2ml, Anti-histamine Erythomycine, (Erythromycin), 1g, pd.inj.sol, MacrolideAntibioticNot registered & circulated in Greek MarketNot registered & circulated in Greek MarketAmoxiclav (1+0,20), (Amoxicillin +Clavulanic Acid), 1g +200 mg, inj, Wide Range AntibioticEremfat, ( Rifampicin), 600 mg, iv, Amps. 1 Vial/Bt, Antι-Eremfat, ( Rifampicin), 600 mg, iv, Amps. 1 Vial/Bt, Antι-tuberculotic



SURGICAL ANALGESIA- ANESTHESIA

Fentanyl, (Fentanyl), 2 ml/10 ml, Inj. Sol. Synthetic Opiod Analgesic-Anesthetic.Anesthetic.Ketamine, (Ketamine), 500 mg/ml, Inj.Sol, Anesthetic Not registered & circulated in Greek MarketPethidine, (Pethidine Hydrochroride), 100 mg/ 2ml, Opioid- AnalgesicNot registered & circulated in Greek Market Not registered & circulated in Greek Market Bupivacaina, (Bupivacaine Hydrochroride), 0,005, Sol. Iv. Inj, Local AnestheticNot registered & circulated in Greek Market. Thiopental, (Thiopental Sodium), 1 g, pd.Inj. sd, Barbituric- Anesthetic Thiopental, (Thiopental Sodium), 1 g, pd.Inj. sd, Barbituric- Anesthetic Not registered & circulated in Greek Market



ANTI-PARASITIC PRODUCTS

Benzyl Benzoate emul. ext. u. 25% w/v Bottle x 1 lt


INTERNATIONAL PARTNERS INTERNATIONAL PARTNERS


COLCHICINE IN COVIDCOLCHICINE IN COVID--1919-- A GREEK STUDY A GREEK STUDY

Abstract

https://www.kathimerini.gr/1074608/article/epikairothta/ellada/elpidofora-ta-prwta-apotelesmata-apo-th-xrhsh-kolxikinhs-se-60-ellhnes-as8eneis

Background Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. Methods GRECCO-19 will be prospective, cluster randomized, open-labeled, controlled study. Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of

GRECCO-19 PRELIMINARY RESULTS

As the professor of cardiology Ch. Stefanadis reveals, in APE-BPE, “the data that we had processed until last night, are very encouraging. CRP inflammatory markers are statistically significant. Eosinophils fall.

Indicators such as troponin, which indicates damage to the myocardium, also fall. All PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Conclusions GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (The study has been submitted to clinicaltrials.gov on March 26, 2020)

The first publication regarding rationale and study design of GRECCO-19 is online in

Indicators such as troponin, which indicates damage to the myocardium, also fall. All of this suggests that it is a very important adjunct to coronary artery disease patients at risk for catastrophic complications such as myocardial and lung collapse.

The double-blind observation study started two weeks ago in our country. It involves 120 patients, 60 of whom are taking colchicine in addition to their medication (drug cocktail) and another 60 who are not taking this well-known drug that has been used The first publication regarding rationale and study design of GRECCO-19 is online in

Hellenic Journal of Cardiology (Elsevier). Potential pathophysiologic mechanisms are also described.

Hellenic J Cardiol. 2020 Apr 3. pii: S1109-9666(20)30061-0. doi: 10.1016/j.hjc.2020.03.002.

cocktail) and another 60 who are not taking this well-known drug that has been used for years to treat pericarditis, an inflammation of the myocardium. "The first data from our patients in Greece are very encouraging, as we have seen a reduction in inflammation," said Stefanakis.


COLCHICINE IN COVIDCOLCHICINE IN COVID--1919-- A CANADIAN STUDY A CANADIAN STUDY

Researchers study drug to reduce COVID-19 complications Issued on:23/03/2020 -17:52Modified:23/03/2020 -17:51 Montreal (AFP) Canadian researchers launched a study Monday into the use of a powerful anti-Canadian researchers launched a study Monday into the use of a powerful anti-inflammatory drug to reduce the risks of pulmonary complications and death related to the new coronavirus. Several COVID-19 patients have had severe complications from a surge of activated immune cells in the lungs --known as a "cytokine storm." In a cytokine storm, the immune system overreacts and damages lung tissue, leading to acute respiratory distress and multi-organ failure. A team led by Jean-Claude Tardif, director of the Montreal Heart Institute research A team led by Jean-Claude Tardif, director of the Montreal Heart Institute research center and professor of medicine at the University of Montreal, are hoping the drug colchicine will work to moderate the overproduction of immune cells and their activating compounds --called cytokines --in COVID-19 patients. If it proves to be successful, the drug --which is already used to treat gout and pericarditis (inflammation of the heart membrane), and is readily available and inexpensive --could become a key tool in the pandemic fight.

SOURCE

https://www.france24.com/en/20200323-researchers-study-drug-to-reduce-covid-

19-complications


CONTACT USCONTACT US

KARIAN PHARMACEUTICALS P.C.

Paradeisou 3,Paradeisou 3,

15342 Agia Paraskevi

Athens, Greece

Tel. +30 210 6003008

Fax. +30 210 6003048

E-mail. [email protected]

www. karian.gr


company profile · company profile 1. about the company karian pharmaceuticals is a fast growing...

Documents